Sign in
CompletedNo phase

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Key facts

Who runs it
Capital Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
86 people enrolled
Started
12 Dec 2024
Ended
12 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MxA tests
  • MxA feedback
  • Follow-up at Day 30
Record updated
4 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • ≥ 18 years old
  • With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapid antigen test or RT-PCR
  • Duration of infection ≤14 days for non-severe patients and < 28 days for patients with severe infections
  • Currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment

Who cannot take part

  • Received interferon therapy within 30 days before screening
  • Systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery
  • Received vaccine in the past 30 days
  • Active tuberculosis
  • Co-infected with influenza and COVID-19
  • Current endotracheal intubation and mechanical ventilation
  • Current vasopressor use
  • Known immunosuppression
  • With contraindications for antiviral treatment
  • Unable to obtain eligible samples

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.

The 2 groups in the trial

  • MxA groupTreatment being tested

    Perform MxA test; MxA results reported to attending clinicians; Provide MxA-based guidelines on antiviral treatment to attending clinicians; Telephone Visit at Day 30

    Treatment: MxA tests, MxA feedback, and Follow-up at Day 30

  • Control groupExisting treatment, for comparison

    Telephone Visit at Day 30

    Treatment: Follow-up at Day 30

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Application of Myxovirus Resistance Protein A in Antiviral Treatment Guidance of Respiratory Viral Infections
Record updated
4 March 2026